항균제 내성 진단 시장 : 병원체별, 기술별, 지역별 동향과 전략 - 경영진 및 컨설턴트용 가이드 포함(2026-2030년)

Report Overview:

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. Will these technologies solve the problem before new antibiotics come along? New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile over 30 companies, large and small, working in this area.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1 Market Guides

• 1.1 Antimicrobial Resistance - Strategic Situation Analysis
• 1.2 Guide for Executives and Business Development Staff
• 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

• 2.1 The Threat and Opportunity of Antimicrobial Resistance
• 2.2 Defining the Opportunity
  • 2.2.1 Revenue Market Size
• 2.3 Methods and Sources
  • 2.3.1 Methodology
  • 2.3.2 Sources
  • 2.3.3 Authors
• 2.4 Perspective: Healthcare and the IVD Industry
  • 2.4.1 Global Healthcare Spending
• 2.5 Spending on Diagnostics
  • 2.5.1 Important Role of Insurance for Diagnostics

3 Overview of a Dynamic Market

• 3.1 Players in a Dynamic Market
  • 3.1.1 Diagnostic Test Developer
  • 3.1.2 Instrumentation Supplier
  • 3.1.3 Chemical/Reagent Supplier
  • 3.1.4 Pathology Supplier
  • 3.1.5 Independent Clinical Laboratory
  • 3.1.6 Public National/regional Laboratory
  • 3.1.7 Hospital Laboratory
  • 3.1.8 Physicians Office Lab (POLS)
  • 3.1.9 Audit Body
  • 3.1.10 Certification Body
• 3.2 Understanding Antimicrobial Resistance
  • 3.2.1 What is Antimicrobial Resistance (AMR)
  • 3.2.2 Bacteria and Other Microbes
  • 3.2.3 The History of Antibiotics
  • 3.2.4 The Role of Animal Husbandry
  • 3.2.5 The Implications of Horizontal Transfer
  • 3.2.6 The Threat of AMR
• 3.3 The Changing Road to New Antibiotics & Technologies
• 3.4 The Key Role of Diagnostics in AMR

4 The Market Opportunity of AMR

• 4.1 The Key Large Market Opportunities in AMR
  • 4.1.1 Streptococcus Pneumoniae (DRSP)
  • 4.1.2 Campylobacter (DRC)
  • 4.1.3 Clostridium Difficile (CD)
  • 4.1.4 Staphylococcus aureus (MRSA)
  • 4.1.5 Neisseria gonorrhoeae (DRNG)
  • 4.1.6 Salmonella (DRNTS)
• 4.2 Diagnostic Technology Development Opportunities
  • 4.2.1 What's Wrong with Microbiology
  • 4.2.2 The Features Battleground of Infectious Disease Diagnostics
  • 4.2.3 Multiplex vs. POC/Rapid
  • 4.2.4 The Miracle of Genetics
  • 4.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation
  • 4.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing.
  • 4.2.7 Markers of Resistance.
  • 4.2.8 What Happens to the Microbiology Lab?

5 Antibiotic Resistance Diagnostics Recent Developments

• 5.1 Antibiotic Resistance Recent Developments
  • 5.1.1 Importance of These Developments
  • 5.1.2 How to Use This Section
• 5.2 DeepUll Raises Euro 50M in Oversubscribed Round
• 5.3 BioMerieux Gets Clearance for ID/AST System
• 5.4 New antibiotics could treat 'super bugs'
• 5.5 Cepheid, Fleming Partner to Address AMR
• 5.6 Fuse Dx and Prompt Dx Funded for POC Tests
• 5.7 FDA Approval for Karius
• 5.8 Presymptom Health Develops Sepsis Test
• 5.9 Visby Medical to Develop STI and AMR MDx
• 5.10 Siemens Healthineers to Develop NGS-Based Sepsis Test
• 5.11 Researchers Developing POC Test for Detecting Risk SNPs
• 5.12 Curetis, FIND Extend AMR Research
• 5.13 Delve Bio to Develop Metagenomic Dx
• 5.14 BioMerieux, Oxford Nanopore Form ID Dx Pact
• 5.15 DnaNudge, Mylab Forge Dx Partnership
• 5.16 FDA Clears New bioMerieux Diagnostic System and Panel
• 5.17 Selux Diagnostics Phenotyping System Gets FDA Approval
• 5.18 New diagnostics to tackle drug resistant infections
• 5.19 Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels
• 5.20 Three companies join forces to tackle antimicrobial resistance (AMR)
• 5.21 T2 Biosystems Exercises BARDA Option
• 5.22 OpGen to Ramp up Use of Acuitas AMR Gene Panel
• 5.23 BD Partners With Pfizer, Wellcome to Study AMR Dx
• 5.24 Sepsis Test Developers Accelerate Plans
• 5.25 OpGen Receives FDA Clearance for AMR Panel
• 5.26 Visby Medical - Rapid Uptake of Handheld PCR Test for STIs
• 5.27 MicroGenDx, OrthoKey Clinic and OrthoKey Surgery
• 5.28 BioMerieux Receives CE Mark for Vitek Clinical Microbiology System
• 5.29 Hologic to Acquire Mobidiag
• 5.30 Campylobacter strains exchange genes
• 5.31 Disinfection spreads antimicrobial resistance
• 5.32 Molzym, Fraunhofer Developing Rapid Sepsis Dx
• 5.33 Illumina, IDbyDNA Build NGS-Based Respiratory Panel
• 5.34 Accelerate Diagnostics Expands AMR Testing
• 5.35 Rapid diagnostics linked to optimal antibiotics
• 5.36 Visby Medical Wins AMR Diagnostic Competition
• 5.37 DNAe Technology SARS-CoV-2 Sequences
• 5.38 Infections with foodborne bacteria becoming harder to treat
• 5.39 Dust is sharing antibiotic resistance genes

6 Key AMR Diagnostics Companies

• 6.1 1928 Diagnostics
• 6.2 Abbott Laboratories
• 6.3 Accelerate Diagnostics
• 6.4 ADT Biotech
• 6.5 Beckman Coulter Diagnostics (Danaher)
• 6.6 Becton, Dickinson and Company
• 6.7 Binx Health
• 6.8 bioMerieux Diagnostics
• 6.9 Bio-Rad Laboratories, Inc.
• 6.10 Cepheid (Danaher)
• 6.11 Curetis (OpGen)
• 6.12 Day Zero Diagnostics.
• 6.13 DeepUII Diagnostics
• 6.14 DNAe
• 6.15 Enzo Biochem
• 6.16 Eurofins Scientific
• 6.17 Fusion Genomics.
• 6.18 GeneFluidics
• 6.19 Genetic Signatures
• 6.20 Great Basin Scientific, Inc
• 6.21 Hologic
• 6.22 Hutman Diagnostics
• 6.23 Inflammatix
• 6.24 Linear Diagnostics
• 6.25 Lumos Diagnostics
• 6.26 MGI
• 6.27 Millipore Sigma
• 6.28 OpGen
• 6.29 Pathogenomix
• 6.30 Qiagen
• 6.31 QuidelOrtho
• 6.32 Revvity
• 6.33 Roche Diagnostics
• 6.34 Scope Fluidics
• 6.35 SeLux Diagnostics
• 6.36 Sherlock Biosciences
• 6.37 Siemens Healthineers
• 6.38 Sysmex
• 6.39 Thermo Fisher Scientific
• 6.40 Uniogen
• 6.41 Vela Diagnostics
• 6.42 Visby Medical

7 The Global Market for Antimicrobial Resistance Diagnostics

• 7.1 Global Market Overview by Country
  • 7.1.1 Table - Global Market by Country
  • 7.1.2 Chart - Global Market by Country
• 7.2 Global Market by Technology - Overview
  • 7.2.1 Table - Global Market by Pathogen
  • 7.2.2 Chart - Global Market by Pathogen - Base/End Year Comparison
  • 7.2.3 Chart - Global Market by Pathogen - Base Year
  • 7.2.4 Chart - Global Market by Pathogen - End Year
  • 7.2.5 Chart - Global Market by Pathogen - Share by Year
  • 7.2.6 Chart - Global Market by Pathogen - Segment Growth
• 7.3 Global Market by Technology - Overview
  • 7.3.1 Table - Global Market by Technology
  • 7.3.2 Chart - Global Market by Technology - Base/End Year Comparison
  • 7.3.3 Chart - Global Market by Technology - Base Year
  • 7.3.4 Chart - Global Market by Technology - End Year
  • 7.3.5 Chart - Global Market by Technology - Share by Year
  • 7.3.6 Chart - Global Market by Technology - Segment Growth

8 Global Antibiotic Resistance Diagnostic Markets - By Pathogen

• 8.1 Drug Resistant Streptococcus Pneumoniae - DRSP
  • 8.1.1 Table DRSP - by Country
  • 8.1.2 Chart - DRSP Growth
• 8.2 Drug Resistant Campylobacter - DRC
  • 8.2.1 Table DRC - by Country
  • 8.2.2 Chart - DRC Growth
• 8.3 Clostridium Difficile - CD
  • 8.3.1 Table CD - by Country
  • 8.3.2 Chart - CD Growth
• 8.4 Methicillin Resistant Staphylococcus Aureus - MRSA
  • 8.4.1 Table MRSA - by Country
  • 8.4.2 Chart - MRSA Growth
• 8.5 Drug Resistant Neisseria Gonorrhoeae - DRNG
  • 8.5.1 Table DRNG - by Country
  • 8.5.2 Chart - DRNG Growth
• 8.6 Drug Resistant Salmonella - DRNTS
  • 8.6.1 Table DRNTS - by Country
  • 8.6.2 Chart - DRNTS Growth

9 Global Antibiotic Resistance Diagnostic Markets - by Technology

• 9.1 Microbiology Culture
  • 9.1.1 Table Culture - by Country
  • 9.1.2 Chart - Culture Growth
• 9.2 Immunoassay
  • 9.2.1 Table Immunoassay - by Country
  • 9.2.2 Chart - Immunoassay Growth
• 9.3 PCR
  • 9.3.1 Table PCR - by Country
  • 9.3.2 Chart - PCR Growth
• 9.4 NGS
  • 9.4.1 Table NGS - by Country
  • 9.4.2 Chart - NGS Growth
• 9.5 Mass Spectrometry - MS
  • 9.5.1 Table MS - by Country
  • 9.5.2 Chart - MS Growth
• 9.6 Rapid and Point of Care - Rapid/POC
  • 9.6.1 Table Rapid/POC - by Country
  • 9.6.2 Chart - Rapid/POC Growth

10 Vision of the Future of AMR Diagnostics

11 Appendices

• 11.1 United States Medicare System: Clinical Laboratory Fees
• Schedule

Table of Tables

• Table 1 Market Players by Type
• Table 2 Known Human Pathogenic Diseases
• Table 3 The Key Market Opportunities
• Table 4 - Market Potential DRSP Diagnostic
• Table 5 - Market Potential DRC Diagnostic
• Table 6 - Market Potential CD Diagnostic
• Table 7 - Market Potential CD Diagnostic
• Table 8 Market Potential DRNG Diagnostic
• Table 9 Market Potential DRNTS Diagnostic
• Table 10 - Key AMR Diagnostics Issues
• Table 11 - Global Market by Region
• Table 12 Global Market by Pathogen
• Table 13 Global Market by Technology
• Table 14 DRSP by Country
• Table 15 DRC by Country
• Table 16 CD by Country
• Table 17 MRSA by Country
• Table 18 DRNG by Country
• Table 19 DRNTS by Country
• Table 20 Culture by Country
• Table 21 Immunoassay by Country
• Table 22 PCR by Country
• Table 23 NGS by Country
• Table 24 MS by Country
• Table 25 Rapid/POC by Country
• Table 26 Clinical Lab Fee Schedule

Table of Figures

• Figure 1 Global Healthcare Spending Map
• Figure 2 The Lab Test Pie
• Figure 3 The Road to Diagnostics
• Figure 4 AMR and Antibiotic Introduction
• Figure 5 The Death Toll of AMR
• Figure 6 Global Market Share Chart
• Figure 7 Global Market by Pathogen - Base vs. End Year
• Figure 8 Global Market by Pathogen Base Year
• Figure 9 Global Market by Pathogen End Year
• Figure 10 Pathogen Share by Year
• Figure 11 Pathogen Segment Growth
• Figure 12 Technology - Base vs. End Year Segment Shift
• Figure 13 Technology Market Base Year
• Figure 14 Technology Market End Year
• Figure 15 Technology Share by Year
• Figure 16 Technology Segment Growth
• Figure 17 DRSP Growth
• Figure 18 DRC Diagnostics Growth
• Figure 19 CD Growth
• Figure 20 MRSA Growth
• Figure 21 DRNG Growth
• Figure 22 DRNTS Growth
• Figure 23 Culture Growth
• Figure 24 Immunoassay Growth
• Figure 25 PCR Growth
• Figure 26 NGS Growth
• Figure 27 MS Growth
• Figure 28 Rapid/POC Growth